IJMPR 2024, 8(3), 51-54

International Journal of Modern Pharmaceutical Research
www.ijmpronline.com

ISSN: 2319-5878
IJMPR
Review Article
SJIF Impact Factor: 5.273

A REHASH TREATISE ON NOVEL HEADWAY IN LYME DISEASE

K. Manasa*[1] and Dr. K. Thirumala Naik[2]

[1]Pharm. D Intern, Pharmacy Practice, Krishna Teja Pharmacy College, Tirupati, Andhra Pradesh.
[2]Associate Professor, Pharmacy Practice, Krishna Teja Pharmacy College, Tirupati, Andhra Pradesh.

Article Received on: 01/01/2024
Article Revised on: 21/01/2024
Article Accepted on: 11/02/2024

***Corresponding Author**
K. Manasa
Pharm. D Intern, Pharmacy Practice, Krishna Teja Pharmacy College, Tirupati, Andhra Pradesh.

ABSTRACT
The most frequent vector borne illness in the country is Lyme disease, which is caused by Borrelia burgdorferi and is mainly spread by Ixodes scapularis, or the deer tick. Nearly 90% of people with symptomatic infection experience its most common manifestation, an erythematous migrans rash that is characterised by its expansion and is occasionally accompanied by myalgia, arthralgia, and malaise. Aseptic meningitis, arthritis, and palsy of the seventh cranial nerve are further symptoms of Lyme disease. A great deal of fear about Lyme disease has been caused by extensive press coverage of its serious symptoms, which is disproportionate to the real morbidity that the disease causes. he frequent use of serological testing to rule out the diagnosis of Lyme disease in individuals with just nonspecific symptoms (such fatigue or arthralgia) who have a very low probability that Lyme disease is the source of their symptoms exacerbates this issue. As a result, incorrect diagnosis occurs frequently and is the main reason why treatments don't work. Based on symptoms treatment was given that is symptomatic treatment was given. For the majority of people with Lyme disease, the prognosis is positive.

KEYWORDS: Lyme Disease (LD), Borrellia burdorferi, tick-borne infections, erythema migrans, serologic testing.

INTRODUCTION
The National Notifiable infections Surveillance System (NNDSS) received reports on 642,602 instances of vector-borne infections between 2004 and 2016, according to the Centers for Disease Control and Prevention (CDC).

In the United States, Lyme borreliosis, or LD, is becoming a more serious health issue. Pathogenic species belonging to the Borreliella genus are the source of LD. By means of tick bites from infected Ixodes spp., these spirochetal bacteria are transferred from vertebrate reservoirs to human hosts. In the USA, Borreliella burgdorferi, sometimes known as B. burgdorferi or Bb, is the most prevalent agent of LD.[2]

Borreliosis, sometimes known as Lyme disease, is a potentially fatal condition that is spread by bacteria from black-legged ticks to humans. A rash may develop at the location where the tick bit you, but as the germs spread, it may also emerge elsewhere.[1]

The red, ring-shaped rash of Erythema migrans at the location of a recent tick bite is indicative of the early localized disease. At this point, other symptoms that may be present include fever, headache, myalgia, arthralgia, malaise, and flu-like symptoms. The majority of individuals only have the early, localised disease's symptoms. The early disseminated disease affects about 20% of individuals; numerous erythema migrans lesions are the most prevalent sign. Flu-like symptoms, lymphadenopathy, arthralgia, myalgia, and lymphocytic meningitis are additional symptoms of the disseminated stage.[3,4]

Bb infections can cause health issues with the skin, joints, neurological system, and, less frequently, the heart if left untreated. While the majority of LD patients recover after receiving antibiotic therapy, some continue to have long-term health issues that may take months or years to resolve.

Since many patients cannot recall ever been bitten by a tick, the diagnosis is not usually straightforward. Patients with the characteristic rash, however, can begin therapy without waiting for serology in endemic areas.[3]

ETIOLOGY
The bacterial spirochete Borrelia burgdorferi is the cause of Lyme disease in the United States, and it is contracted by the bite of an Ixodes genus tick, most frequently Ixodes scapularis. Borrelia burgdorferi, Borrelia afzelii, and Borrelia garinii are the most common causes in Eurasia.

B. Burgdoferi is very fond of the joint. Only in Europe can one find B. garinii, which selectively causes white matter encephalitis. B. afzelli is present at the infection

site and has a preference for the skin.Borrelia is spread via a number of subspecies of Ixodes.[2,3]

PATHOPHYSIOLOGY

The expression of outer surface proteins (Osps) by B. burgdorferi is crucial for the tick's survival as well as for human infection. For B. burgdorferi to adhere to the tick midgut, OspA is necessary.

As the spirochete exits the midgut and travels to the salivary glands before injecting itself into the mammalian host, its expression diminishes during engorgement. OspC expression rises at this time, and it has been suggested that OspC contributes to spirochete infection and migration.

The binding of OspC to human plasminogen may increase the spirochete's capacity to propagate through skin and other tissues. The systemic systems that may be connected to early Lyme disease are produced by this bloodstream-based dispersal from the tick bite site.[4]

Both pro- and anti-inflammatory cytokines are produced by macrophage and T cell infiltrates in humans suffering from erythema migrans. Additionally, there is proof that adaptive T-cell and B-cell responses in lymph nodes during widespread infections result in the production of antibodies against numerous spirochete components.

When B. burgdorferi spreads throughout humans, it binds to specific host integrins and triggers a pro-inflammatory response. This response involves the synthesis of extracellular matrix proteins as well as matrix glycosaminoglycans, which may account for the organism's preference for specific tissues (such as collagen fibrils in the extracellular matrix of the heart, nervous system, and joints).[3,4]



Figure 1: https://media.springernature.com.

SYMPTOMS

Erythema migrans is a sign of an early localised disease that usually presents 3 to 30 days (mostly within 7 to 14 days) after the tick bite.

Starting as a red macule or papule, the lesion grows over several days to weeks into a massive, annular, erythematous lesion with a diameter of at least 5 cm and up to 70 cm (median of 15 cm). The rash often has a uniform erythematous appearance, although it can

sometimes resemble a target lesion with varying degrees of centre clearing.

Its shape is highly variable, and on rare occasions, the centre may feature necrotic or vesicular patches. The majority of the time, erythema migrans is asymptomatic, but it can also be pruritic or painful. Systemic symptoms including fever, malaise, headaches, stiff necks, myalgia, or arthralgia can also accompany the condition.[4]

The secondary skin lesions are composed of several annular erythematous lesions that resemble the main lesion, but are often smaller. They typically emerge three to five weeks following the tick bite. Meningitis and cranial nerve palsies, particularly facial nerve palsy, are typical early disseminated Lyme disease symptoms. During this stage of Lyme disease, systemic symptoms like fever, headache, myalgia, arthralgia, and exhaustion are also frequently experienced. Heart failure, typically occurs.[4,5]

Figure 2: https://heidenortho.com.

DIAGNOSIS

Clinical characteristics in a person who has visited or resides in an endemic area are used to diagnose Lyme disease. After an Ixodes species tick bite, individuals with early disease and a high pretest likelihood should generally be treated based on their signs and symptoms. Similar to other diseases transmitted by ticks, only 50–70% of patients remember being bitten, frequently due to the small size of deer tick nymphs that are invisible.[5,6]

Depending on the disease's stage, several differential diagnoses for Lyme disease exist. It's important to distinguish erythema migrans, the early stages of Lyme disease, from other skin conditions such as cellulitis, granuloma annulare, ringworm, and inflammation brought on by insect bites. Coxsackie enteroviruses are one type of viral agent that can cause carditis in addition to other reasons. A lengthy differential diagnosis for arthritis include rheumatologic, oncologic, and bacterial septic arthritis.[4]

It is commonly known that there are significant differences in the sensitivity and specificity of antibody testing for Lyme disease. Pre-packaged commercial kits perform far less accurately and reproducibly than tests conducted by "reference" laboratories, which frequently create the test materials and uphold strict quality control. When ordering antibody tests for Lyme disease, clinicians should follow official guidelines from the CDC and the Second National Conference on Serologic Diagnosis of Lyme Disease. First, they should order a sensitive screening test, like an enzyme-linked immunosorbent assay (ELISA), and if the result is positive or unclear, they should then order a Western immunoblot to confirm the result.[4]

TREAMENT

The Infectious Diseases Society of America's guidelines2 state that doxycycline (100 mg orally, twice daily) for non-pregnant patients and amoxicillin (50 mg/kg per day orally) for patients younger than 9 years old are recommended antibiotic treatments for Lyme disease. These treatments are generally effective in the early stages of the illness. For adults, amoxicillin (500 mg orally, three times a day) is the second-choice treatment. Cefuroxime axetil (twice daily, 500 mg oral; or 30 mg/kg).[4,5]

The optimum course of treatment for an early condition characterised by erythema migrans is to take amoxicillin or doxycycline orally for 14 days; however, there is some evidence that 10 days of therapy may be sufficient. Oral medicines can also be used in the treatment of early disseminated illness in outpatients without total heart

block who have been diagnosed with carditis, multiple erythema migrans, or localised cranial nerve palsy. When the condition is advanced and presents as arthritis, oral therapy using amoxicillin or doxycycline usually works effectively. The patient may benefit symptomatically from further non-steroidal anti-inflammatory medicine treatment.[4]

For Lyme meningitis, intravenous ceftriaxone treatment is frequently utilised. On the other hand, European research indicates that oral doxycycline for Lyme meningitis is just as effective as ceftriaxone. Myocarditis and heart block in symptomatic patients needing hospitalisation are additional indications for ceftriaxone use. These patients can finish their treatment with an oral medication after their symptoms go better. Doxycycline should not be administered to children under the age of eight years old since it may result in permanent tooth discolouration.

Doxycycline patients should be informed that when taking the drug, they run the risk of getting dermatitis in parts of their body that are exposed to the sun. Cefuroxime is an approved treatment for Lyme disease and a substitute for people allergic to penicillin and unable to use doxycycline. Since azithromycin is less effective than other oral medications, it should only be used in situations where using the other antimicrobials is clearly contraindicated. Because of the outstanding outcomes of treatment with either amoxicillin or doxycycline, there is minimal need to employ newer medicines.[7]

PREVENTION

The most obvious way to prevent B burgdorferi infection is to avoid tick bites. It is recommended that people wear protective clothing and use tick repellent containing N, N-diethyl-m-toluamide (DEET) if they must be outside in places where Ixodes ticks are present. Additionally, removing ticks as soon as possible and regularly checking the skin should reduce the chance of infection. There is, however, a dearth of information on these strategies' effectiveness. Additional actions, such as clearing or burning plants in tick-harboring.[4,5]

REFERENCES

1. Alana Biggers, M.D., MPH (LYME DISEASE) Updated on May 24, 2023.
2. Alexandra Benisek , Shoshana Siegel, Brunilda Nazario, MD (Lyme Disease Important Facts to Know) on August 08, 2023.
3. Gwenn L. Skar; Kari A. Simonsen (Lyme Disease) Updated on November 15, 2023.
4. Thomas S. Murray, MD PhD[1] and Eugene D. Shapiro, MD(Lyme Disease) updated on PMC, 2013 May 13.
5. Robert L. Bratton MD, JohnW. Whiteside MD, MichaelJ. H ovan MD, Richard L. Engle MD, Frederick D. Edwards MD (Diagnosis and Treatment of Lyme Disease) updated on, May 2008.
6. David Pitrak, MD[1]; Cynthia T. Nguyen, PharmD[1] Adam S. Cifu, MD[1] (Diagnosis of Lyme Disease) February 15, 2022.
7. Eugene D. Shapiro, Michael A. Gerber (Lyme Disease) updated on, 01 August 2000.